Etzer Darout
Stock Analyst at Barclays
(4.95)
# 136
Out of 5,032 analysts
531
Total ratings
57.5%
Success rate
30.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Maintained: Buy | $78 | $42.39 | +84.01% | 2 | Oct 7, 2026 | |
| SMMT Summit Therapeutics | Reiterated: Hold | $18 → $20 | $17.31 | +15.54% | 14 | Oct 1, 2026 | |
| IOVA Iovance Biotherapeutics | Reiterated: Buy | $15 | $12.96 | +15.74% | 14 | Sep 29, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterated: Buy | $148 | $88.22 | +67.76% | 12 | Sep 22, 2026 | |
| ANAB AnaptysBio | Reiterated: Buy | $75 | $47.89 | +56.61% | 14 | Sep 22, 2026 | |
| CLDX Celldex Therapeutics | Reiterated: Buy | $53 | $31.01 | +70.94% | 9 | Sep 22, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $160 | $80.18 | +99.55% | 9 | Sep 21, 2026 | |
| SRRK Scholar Rock Holding | Downgraded: Hold | $55 → $58 | $42.45 | +36.63% | 21 | Sep 14, 2026 | |
| LEGN Legend Biotech | Reiterated: Buy | $78 → $74 | $18.72 | +295.30% | 12 | Sep 11, 2026 | |
| MNPR Monopar Therapeutics | Reiterated: Buy | $128 → $145 | $79.57 | +82.23% | 10 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $35 | $24.36 | +43.68% | 33 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $270 → $271 | $231.39 | +17.12% | 8 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $10.53 | +165.91% | 15 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $407 → $415 | $362.78 | +14.39% | 10 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $31.39 | +107.07% | 6 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $153 → $180 | $138.69 | +29.79% | 12 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $3 | $1.08 | +177.78% | 10 | Aug 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $3.64 | +64.84% | 34 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.88 | +143.06% | 30 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $10.56 | +165.15% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $2.56 | +525.00% | 31 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $14 | $16.79 | -16.62% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 → $30 | $18.74 | +60.09% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $49 | $58.33 | -16.00% | 34 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $11.60 | +158.62% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $7.31 | +173.60% | 36 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $17.37 | +113.01% | 15 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $134 → $139 | $112.73 | +23.30% | 17 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $119 | $105.98 | +12.29% | 5 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $3.46 | n/a | 1 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $143 | $95.73 | n/a | 10 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.86 | n/a | 10 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.29 | n/a | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.97 | n/a | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $37.80 | n/a | 11 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $22.60 | n/a | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $140.79 | n/a | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.11 | n/a | 4 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $63 | $0.5601 | n/a | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $37 | $79.25 | n/a | 2 | Sep 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $7 | - | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $0.52 | n/a | 1 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $25 | $8.13 | n/a | 2 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $48 | $2.56 | n/a | 2 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €23.13 → €26.69 | €2.97 | n/a | 2 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $162 | $223.94 | n/a | 1 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $25.65 | n/a | 4 | Jul 14, 2020 |
Enliven Therapeutics
Oct 7, 2026
Maintained: Buy
Price Target: $78
Current: $42.39
Upside: +84.01%
Summit Therapeutics
Oct 1, 2026
Reiterated: Hold
Price Target: $18 → $20
Current: $17.31
Upside: +15.54%
Iovance Biotherapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $15
Current: $12.96
Upside: +15.74%
ABIVAX Société Anonyme
Sep 22, 2026
Reiterated: Buy
Price Target: $148
Current: $88.22
Upside: +67.76%
AnaptysBio
Sep 22, 2026
Reiterated: Buy
Price Target: $75
Current: $47.89
Upside: +56.61%
Celldex Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: $53
Current: $31.01
Upside: +70.94%
Oruka Therapeutics
Sep 21, 2026
Reiterated: Buy
Price Target: $160
Current: $80.18
Upside: +99.55%
Scholar Rock Holding
Sep 14, 2026
Downgraded: Hold
Price Target: $55 → $58
Current: $42.45
Upside: +36.63%
Legend Biotech
Sep 11, 2026
Reiterated: Buy
Price Target: $78 → $74
Current: $18.72
Upside: +295.30%
Monopar Therapeutics
Sep 11, 2026
Reiterated: Buy
Price Target: $128 → $145
Current: $79.57
Upside: +82.23%
Sep 11, 2026
Reiterated: Buy
Price Target: $27 → $35
Current: $24.36
Upside: +43.68%
Sep 10, 2026
Reiterated: Buy
Price Target: $270 → $271
Current: $231.39
Upside: +17.12%
Sep 10, 2026
Reiterated: Buy
Price Target: $28
Current: $10.53
Upside: +165.91%
Sep 10, 2026
Reiterated: Buy
Price Target: $407 → $415
Current: $362.78
Upside: +14.39%
Sep 3, 2026
Reiterated: Buy
Price Target: $65
Current: $31.39
Upside: +107.07%
Aug 31, 2026
Reiterated: Buy
Price Target: $153 → $180
Current: $138.69
Upside: +29.79%
Aug 20, 2026
Reiterated: Sell
Price Target: $3
Current: $1.08
Upside: +177.78%
Aug 14, 2026
Reiterated: Buy
Price Target: $6
Current: $3.64
Upside: +64.84%
Aug 12, 2026
Reiterated: Buy
Price Target: $7
Current: $2.88
Upside: +143.06%
Aug 7, 2026
Reiterated: Buy
Price Target: $28
Current: $10.56
Upside: +165.15%
Aug 7, 2026
Reiterated: Buy
Price Target: $16
Current: $2.56
Upside: +525.00%
Aug 7, 2026
Reiterated: Sell
Price Target: $14
Current: $16.79
Upside: -16.62%
Aug 7, 2026
Reiterated: Buy
Price Target: $27 → $30
Current: $18.74
Upside: +60.09%
Aug 6, 2026
Reiterated: Hold
Price Target: $49
Current: $58.33
Upside: -16.00%
Aug 6, 2026
Reiterated: Buy
Price Target: $30
Current: $11.60
Upside: +158.62%
Aug 5, 2026
Reiterated: Buy
Price Target: $20
Current: $7.31
Upside: +173.60%
Aug 5, 2026
Reiterated: Buy
Price Target: $37
Current: $17.37
Upside: +113.01%
Jul 28, 2026
Reiterated: Buy
Price Target: $134 → $139
Current: $112.73
Upside: +23.30%
Dec 8, 2025
Reiterated: Buy
Price Target: $70 → $119
Current: $105.98
Upside: +12.29%
Apr 4, 2025
Reiterated: Buy
Price Target: $9
Current: $3.46
Upside: n/a
Mar 11, 2025
Reiterated: Buy
Price Target: $130 → $143
Current: $95.73
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.86
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $2.29
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $1.97
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $37.80
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $22.60
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $140.79
Upside: n/a
Mar 4, 2025
Rated: Hold
Price Target: n/a
Current: $8.11
Upside: n/a
Feb 27, 2025
Initiated Coverage: Buy
Price Target: $63
Current: $0.5601
Upside: n/a
Sep 13, 2021
Reiterated: Buy
Price Target: $38 → $37
Current: $79.25
Upside: n/a
May 18, 2021
Initiated Coverage: Buy
Price Target: $7
Current: -
Upside: n/a
May 18, 2021
Initiated Coverage: Buy
Price Target: $60
Current: $0.52
Upside: n/a
Mar 17, 2021
Reiterated: Buy
Price Target: $16 → $25
Current: $8.13
Upside: n/a
Mar 11, 2021
Reiterated: Buy
Price Target: $50 → $48
Current: $2.56
Upside: n/a
Mar 5, 2021
Reiterated: Buy
Price Target: €23.13 → €26.69
Current: €2.97
Upside: n/a
Feb 22, 2021
Downgraded: Hold
Price Target: $162
Current: $223.94
Upside: n/a
Jul 14, 2020
Reiterated: Buy
Price Target: $48
Current: $25.65
Upside: n/a